Reported Friday, MannKind's Afrezza Data At ADA Highlight Pediatric Safety, Gestational Diabetes Efficacy And AID System Compatibility Following May 2026 FDA Pediatric Approval

Mannkind

Mannkind

MNKD

0.00
  • Builds on recent FDA approval (May 29, 2026) of Afrezza for use in children and adolescents aged 6 and older living with type 1 and type 2 diabetes
  • New data and real-world findings further emphasize pediatric safety, glycemic control and treatment satisfaction
  • Exploratory analysis of inhaled insulin used with AID systems provides insight on the impact of total daily dose algorithms
  • Data from randomized cross-over trial supports safety and efficacy of inhaled insulin as an alternative to RAA in gestational diabetes
This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.